News | Coronavirus (COVID-19) | July 05, 2022

How the Coronavirus Attacks the Heart

A research team at RUB has discovered the mechanisms by which the coronavirus attacks the heart – and how it could be stopped.

A medical researcher at RUB has discovered how the coronavirus enters the heart muscle cells. © Roberto Schirdewahn 


July 5, 2022 — The International Journal of Cardiology published an article on the findings of how the Coronavirus attacks the heart, which occurs mainly in patients with comorbidities such as obesity, diabetes and hypertension. 

Virus Detected in Heart Cells 

In order to track down the new entry mechanism, the research team at the university hospital used histochemical methods and microscopy to analyze heart tissue structures from patients suffering from COVID-19 and those who died from or with the disease. In a first step, they provided evidence that the virus can indeed be detected directly in the cells of the heart muscle. “Our observations show that the virus exerts pressure on the heart muscle, attacks and weakens the contractile force, i.e. the pumping function of the heart,” said Nazha Hamdani, head of the research department for molecular and experimental cardiology at the Bochum University Hospital

But how does the virus enter the heart? What mechanisms facilitate the penetration of the virus into the heart muscle cells? The Bochum team showed that one possible mechanism of cardiac muscle cell dysfunction in Sars-Cov-2 patients is the activation of certain enzymes that degrade proteins. In fact, the team detected an increased so-called proteolytic activity. 

This suggests that Sars-Cov-2 enters cells as a result of the activation of the spike protein by enzymes responsible for the degradation of proteins, and that its entry into cells depends on these degradation enzymes. In addition, Hamdani’s group investigated proteins that are responsible for apoptosis, i.e. cellular suicide. The team showed that while the apoptotic proteins had increased activity, their expression was drastically reduced. “This indicates that the proteins are cleaved and apoptosis is activated,” explained Hamdani. “The results imply that apoptosis contributes to the deterioration in cardiac contractility observed in Sars-Cov-2 patients.” 

The Key Role of Inflammation and Oxidative Stress 

In the next step, the team set out to explore what promotes the increased proteolytic activity and apoptosis of cardiac myocytes. The study showed that oxidative stress and a pro-inflammatory environment exacerbate the damage associated with Sars-Cov-2. The focus here was on the so-called neutrophils. Neutrophils are one of the primary cell types that release proteolytic enzymes. They play an essential role during an inflammatory response. They are rapidly mobilized from the bloodstream into the damaged tissue. Since proteolytic enzymes are released more frequently in Sars-Cov-2 patients, Hamdani’s team analyzed the signaling pathway, more specifically the interleukin-6-driven neutrophil traffic. The researchers found that inflammatory signaling pathways in cardiac myocytes were highly regulated – i.e. interleukin-6 was highly elevated – suggesting a key role for these white blood cells in COVID-19 and associated inflammatory pathologies

Alternative Gateways 

Furthermore, the Bochum-based researchers have backed the existing findings that the virus also uses the protein neuropilin-1 (NRP-1) as a gateway into the cells. Hamdani’s research shows that the coronavirus thus has several mechanisms at its disposal to spread in human organs. “Sars-Cov-2 is able to spread in the infected heart in a receptor-dependent and receptor-independent manner. We also examined another mechanism by which the virus can gain access to the heart muscle cells, thus contributing to endothelial dysfunction. We will soon be able to publish these results,” concluded Hamdani. 

For more information: https://www.ruhr-uni-bochum.de/en 

Related Long-COVID Content:  

MRI Sheds Light on COVID Vaccine-Associated Heart Muscle Injury  

What We Know About Cardiac Long-COVID Two Years Into the Pandemic   

VIDEO: Long-term Cardiac Impacts of COVID-19 Two Years Into The Pandemic — Interview with Aaron Baggish, M.D.  

VIDEO: Long-COVID Presentations in Cardiology at Beaumont Hospital — Interview with Justin Trivax, M.D.  

VIDEO: Cardiac Presentations in COVID Long-haulers at Cedars-Sinai Hospital — Interview with Siddharth Singh, M.D.  

Find more COVID news and videos  

Related COVID Content:  

COVID-19 Fallout May Lead to More Cancer Deaths  

Kawasaki-like Inflammatory Disease Affects Children With COVID-19  

FDA Adds Myocarditis Warning to COVID mRNA Vaccine Clinician Fact Sheets  

CMS Now Requires COVID-19 Vaccinations for Healthcare Workers by January 4  

Cardiac MRI of Myocarditis After COVID-19 Vaccination in Adolescents  

Small Number of Patients Have Myocarditis-like Illness After COVID-19 Vaccination  

Overview of Myocarditis Cases Caused by the COVID-19 Vaccine  

Case Study Describes One of the First U.S. Cases of MIS-C  

NIH-funded Project Wants to Identify Children at Risk for MIS-C From COVID-19  


Related Content

News | Cardiovascular Clinical Studies

Nov. 18, 2024 — Silence Therapeutics presented end-of-treatment data from its Phase 2 ALPACAR-360 study of zerlasiran, a ...

Home November 18, 2024
Home
News | Cardiovascular Clinical Studies

Aug. 15, 2024 — According to a new study being presented at ACC Asia 2024 in Delhi, India, drinking over 400 mg of ...

Home August 14, 2024
Home
Videos | Cardiovascular Clinical Studies

As part of DAIC's continuing Thought Leadership Series, this month Editorial Director Melinda Taschetta-Millane sits ...

Home July 30, 2024
Home
News | Cardiovascular Clinical Studies

July 25, 2024 — BioCardia, Inc., a global leader in cellular and cell-derived therapeutics for the treatment of ...

Home July 25, 2024
Home
News | Cardiovascular Clinical Studies

July 18, 2024 — Elucid, a pioneering AI medical technology company providing physicians with imaging analysis software ...

Home July 18, 2024
Home
News | Cardiovascular Clinical Studies

July 10, 2024 — CellProthera, a private company specializing in cell-based therapies for repairing ischemic tissues, and ...

Home July 10, 2024
Home
News | Cardiovascular Clinical Studies

July 9, 2024 — Microbot Medical Inc. announced the completion of the first procedure in a patient utilizing its LIBERTY ...

Home July 09, 2024
Home
News | Cardiovascular Clinical Studies

June 26, 2024 — Semaglutide, a medication initially developed for type 2 diabetes and obesity, significantly improves ...

Home June 26, 2024
Home
News | Cardiovascular Clinical Studies

June 21, 2024 — Lexicon Pharmaceuticals, Inc. announced that the peer-reviewed Journal of the American College of ...

Home June 21, 2024
Home
News | Cardiovascular Clinical Studies

June 20, 2024 — Microbot Medical Inc. announced its agreement with Brigham and Women’s Hospital (BWH), a leading ...

Home June 20, 2024
Home
Subscribe Now